This established that SIRPα negatively regulates ADP responses in NLCs derived from CLL patients and suggests that SIRPα could potentially be targeted to reinstate sensitivity to obinutuzumab. The gene discussed is SIRPA; the disease is B-cell chronic lymphocytic leukemia.